2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists
摘要:
Recently, we disclosed 4-aminoquinolines as structurally novel NR1/2B subtype selective NMDA receptor antagonists. We would now like to report our findings on structurally related pyridine analogues. The SAR developed in this series resulted in the discovery of high affinity antagonists which are selective (vs alpha1 and M1 receptors) and active in vivo. (C) 2003 Elsevier Science Ltd. All rights reserved.
The invention relates to compounds of formulae
1
Compounds of the invention have a good affinity to the NMDA receptor and are useful for the treatment of diseases related to this receptor.
[EN] PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE PYRIDINE UTILISÉS COMME LIGANDS DU RÉCEPTEUR NMDA
申请人:HOFFMANN LA ROCHE
公开号:WO2003040128A1
公开(公告)日:2003-05-15
The invention relates to compounds of formulas (IA) or (IB) wherein R1 and R2 are independently from each other hydrogen, lower alkyl, -(CH2)n-OH, -(CH2)n-N(R6)2, -NR6C(O)C(O)O-lower alkyl, -NR6-(CH2)n-OH, -NR6C(O)-lower alkyl, -NH-benzyl or NR6C(O)-(CH2)n-OH; R6 is independently from each other hydrogen or lower alkyl R' is hydrogen or lower alkyl; R3 is hydrogen or amino; R4 is hydrogen or lower alkyl; R5 is hydrogen or halogen; or R1 and R' may be together with the carbon atoms to which they are attached the group (CH2)4-; or R2 and R3 may be together with the carbon atoms to which they are attached the group -N(R6)-CH2-O-CH2-; n is 0, 1, 2 or 3; and to pharmaceutically acceptable acid addition salts thereof. It has been shown that these compounds have a good affinity to the NMDA receptor and they may therefore be used for the treatment of diseases, related to this receptor.
2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists
Recently, we disclosed 4-aminoquinolines as structurally novel NR1/2B subtype selective NMDA receptor antagonists. We would now like to report our findings on structurally related pyridine analogues. The SAR developed in this series resulted in the discovery of high affinity antagonists which are selective (vs alpha1 and M1 receptors) and active in vivo. (C) 2003 Elsevier Science Ltd. All rights reserved.